Northern Oak Wealth Management Inc. Has $107,000 Holdings in Amgen, Inc. (NASDAQ:AMGN)

Northern Oak Wealth Management Inc. lessened its stake in Amgen, Inc. (NASDAQ:AMGN) by 25.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 580 shares of the medical research company’s stock after selling 200 shares during the quarter. Northern Oak Wealth Management Inc.’s holdings in Amgen were worth $107,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the company. Bray Capital Advisors lifted its position in shares of Amgen by 11.6% in the second quarter. Bray Capital Advisors now owns 19,676 shares of the medical research company’s stock worth $3,626,000 after purchasing an additional 2,045 shares in the last quarter. Weaver Consulting Group bought a new stake in shares of Amgen in the first quarter worth $239,000. CHICAGO TRUST Co NA lifted its position in shares of Amgen by 2.8% in the second quarter. CHICAGO TRUST Co NA now owns 3,716 shares of the medical research company’s stock worth $685,000 after purchasing an additional 100 shares in the last quarter. Phocas Financial Corp. bought a new stake in shares of Amgen in the fourth quarter worth $117,000. Finally, Calton & Associates Inc. lifted its position in shares of Amgen by 17.8% in the second quarter. Calton & Associates Inc. now owns 1,770 shares of the medical research company’s stock worth $326,000 after purchasing an additional 268 shares in the last quarter. Institutional investors own 77.43% of the company’s stock.

In other Amgen news, Director R Sanders Williams sold 425 shares of the company’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $183.04, for a total transaction of $77,792.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at $2,990,141.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total transaction of $375,160.00. Following the sale, the director now directly owns 16,336 shares in the company, valued at $3,064,306.88. The disclosure for this sale can be found here. Insiders have sold 4,425 shares of company stock worth $804,312 over the last ninety days. Insiders own 0.25% of the company’s stock.

A number of analysts have recently commented on the stock. JPMorgan Chase & Co. reissued a “hold” rating and issued a $190.00 price objective on shares of Amgen in a research report on Wednesday, May 15th. Oppenheimer set a $210.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, May 24th. Mizuho reissued a “buy” rating and issued a $208.00 price objective on shares of Amgen in a research report on Monday, July 1st. Credit Suisse Group assumed coverage on shares of Amgen in a research report on Monday, May 20th. They issued an “outperform” rating and a $208.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday, April 15th. Eight investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and an average price target of $210.41.

NASDAQ AMGN traded up $11.02 on Friday, hitting $196.25. 7,791,613 shares of the stock were exchanged, compared to its average volume of 3,041,442. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60. The business has a fifty day simple moving average of $181.68. Amgen, Inc. has a 52 week low of $166.30 and a 52 week high of $210.19. The stock has a market capitalization of $110.07 billion, a P/E ratio of 13.63, a PEG ratio of 2.15 and a beta of 1.19.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. During the same period in the prior year, the firm posted $3.83 earnings per share. The company’s quarterly revenue was down 3.1% compared to the same quarter last year. On average, equities analysts expect that Amgen, Inc. will post 14.23 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 6th. Shareholders of record on Thursday, August 15th will be given a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend is Wednesday, August 14th. Amgen’s dividend payout ratio (DPR) is currently 40.28%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Article: What is a recession?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.